Trajenta Duo

Product Overview

Trajenta Duo is a combination medication containing Linagliptin and Metformin as active ingredients. Designed for type 2 diabetes management, it effectively regulates blood glucose levels. Linagliptin enhances incretin hormone activity, promoting insulin secretion while suppressing glucagon release. Metformin operates by inhibiting hepatic glucose production and enhancing peripheral insulin sensitivity.

Therapeutic Applications

This medication is indicated for adults with type 2 diabetes mellitus as part of a comprehensive treatment plan including diet and exercise. It helps achieve optimal glycemic control when lifestyle modifications alone prove insufficient. Important Note: Trajenta Duo is contraindicated for type 1 diabetes or diabetic ketoacidosis management.

Administration Guidelines

For optimal results and reduced gastrointestinal effects:
• Take tablets with meals
• Swallow whole with water (do not crush/chew)
• Follow prescribed dosage precisely
• Maintain consistent dosing schedule

Dosage adjustments may be necessary based on:
– Renal function
– Glycemic response
– Individual tolerance

Mechanism of Action

The dual-action formula works through:
1. Linagliptin: DPP-4 enzyme inhibition → increased active incretin hormones → enhanced glucose-dependent insulin secretion + reduced glucagon production
2. Metformin:
– Suppresses hepatic gluconeogenesis
– Improves peripheral glucose uptake
– Enhances insulin sensitivity

Dosage Protocol

Standard regimen: Twice daily with meals
Dosage considerations:
• Baseline renal assessment required
• Regular glycemic monitoring recommended
• Gradual titration may be implemented
• Maximum daily dose: As prescribed by physician

Therapeutic Advantages

• Effective blood glucose regulation
• Complementary to lifestyle interventions
• Diabetes complication risk reduction
• Simplified dosing schedule
• Metabolic profile improvement

Potential Adverse Effects

Most common (typically transient):
• Gastrointestinal disturbances (nausea, diarrhea)
• Mild abdominal discomfort

Serious (require immediate medical attention):
• Signs of lactic acidosis
• Hypersensitivity reactions
• Persistent severe symptoms

Important Precautions

Special considerations for:
• Renal impairment patients (contraindicated if eGFR <30) • Hepatic dysfunction cases • Cardiovascular conditions • Elderly population Drug interaction precautions: • Disclose all concurrent medications • Monitor for hypoglycemia with insulin secretagogues • Contrast media procedures require temporary discontinuation

Storage Requirements

• Maintain at controlled room temperature (15-30°C)
• Protect from moisture and light
• Keep in original packaging
• Secure from children/pets access
• Observe expiration dates

Medical Disclaimer

The information provided, while carefully reviewed, serves educational purposes only and does not replace professional medical advice. For complete information regarding:
• Potential side effects
• Drug interactions
• Specific warnings
• Individualized treatment plans

Please consult your healthcare provider. This content aims to facilitate informed patient-physician discussions, not to substitute clinical judgment.